Big step in rapid diagnostics for infectious diseases

Big step in rapid diagnostics
Optimization of the VAIA method. A) Nitrocellulose membranes dotted with target antigens are concentrically placed in a VFD reactor housing a quartz tube (20 mm OD, 17.5 mm ID, 18.5 cm in length). The VFD reactor tube is tilted at 45° and rotated at 1500 rpm throughout the assay steps. At this speed the shear stress is dominated by a spinning top topological fluid flow, as depicted. Membranes are removed from the VFD reactor, and the assay dots are visualized through addition of a colorimetric reagent. B) An indirect phage IA was used to optimize VAIA rotational speed and assay time. Systematic screening of 9 combinations of these parameters revealed 1500 rpm and a 4.5 min assay time (Base Time) yielded the highest signal-to-noise ratios and lowest error. Error bars represent SEM (n=3). C) A direct eGFP-FLAG detection IA was used to compare quantitation with VAIA to the conventional IA method. VAIA was faster, more robust, more sensitive, and less costly than the conventional method. The fluid flow was examined by performing VAIA with either hemispherical-bottom VFD reactors or flat-bottom VFD reactors. Error bars represent SEM for each group of dots on each immunoblot (n=3). Percent coefficients of variation are based upon independent replicates (n=3). Credit: Angewandte Chemie International Edition (2022). DOI: 10.1002/anie.202202021

The speedy, high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing, say U.S. and Flinders University researchers who specialize in "green" vortex fluidic device (VFD) medical applications.

The new method—using the revolutionary VFD developed by Flinders University—can be readily scaled up to test hundreds and "potentially thousands" of proteins in one assay in less than five minutes, says senior researcher University of California, Irvine Professor Gregory Weiss, who is a U.S. leader in VFD experiments and applications.

"Most importantly, the data produced can be accurately read with a —immediately addressing the gap between development and implementation of biomarker-based precision medicine," he says.

While many costly tests can take upwards of 48–72 hours, on-the-spot tests such as this can lead to accurate diagnosis and early commencement of important drug treatments and reduction of wrong medications.

An accessible universal solution to offer rapid personalized mobile testing for infectious diseases—or diagnosis and delivery of targeted treatments for other diseases even in —has so far been out of reach.

"The extreme disparity between technologically lagging and advanced settings directly impacts disease mortality and morbidity, particularly for ," says Flinders University researcher Dr. Xuan Luo, a co-author in a new article on the novel test.

In the published in international chemistry journal Angewandte Chemie, the new method, labeled VFD-accelerated immunoblot (VAIA), was compared and found superior to other PoC biomarker-based tests currently in use.

Not only was the processing faster and accurate, it sliced up to 70% off the cost of sometimes toxic reagents. While many immunoblot assays are used to detect certain diseases, many are not highly sensitive and complex to use—even for technicians in a laboratory or .

In contrast the VAIA was found to improve conventional processing time from hours to less than five minutes, using three major immunoassay formats with purified proteins and biofluids.

More information: Emily C. Sanders et al, Under‐5‐Minute Immunoblot Assays by Vortex Fluidic Device Acceleration, Angewandte Chemie International Edition (2022). DOI: 10.1002/anie.202202021

Citation: Big step in rapid diagnostics for infectious diseases (2022, June 22) retrieved 3 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

A potential at-home COVID-19 test is just as good as laboratory PCR tests, according to preclinical data


Feedback to editors